Clinic
Fast Pace Kentucky PLLC
Fast Pace Kentucky PLLC was paid $23.27M by Medicaid between Jan 2018 and Dec 2024, across 49 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 43% of everything it billed.
33Billing provider infoFAST PACE KENTUCKY PLLC
FRANKLIN, KY 42134
FRANKLIN, KY 42134
33aNPI1457716706assigned 12/30/2015
33bProvider typeUrgent Care Clinic/Center
28Total paid$23.27M
24GClaims778,718
24DCodes billed49
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Urgent Care Clinic/Center providers in Kentucky
Rank by total paid#1 of 13
Median peer was paid$254K
This provider vs. median92×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 142,671 | $4.07M | |
| 2019 | 168,913 | $4.71M | |
| 2020 | 109,025 | $3.20M | |
| 2021 | 174,891 | $7.12M | |
| 2022 | 116,127 | $2.84M | |
| 2023 | 46,654 | $965K | |
| 2024incomplete | 20,437 | $370K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 43% | 245,006 | 214,876 | $10.12M |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 19% | 64,520 | 57,658 | $4.51M |
| 87428 | 13% | 57,666 | 50,867 | $3.05M | |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 5.9% | 53,797 | 47,350 | $1.36M |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 5.4% | 116,451 | 54,477 | $1.25M |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 3.4% | 17,395 | 15,035 | $800K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 3.2% | 75,103 | 66,988 | $752K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2.3% | 30,043 | 26,954 | $534K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.0% | 37,645 | 32,403 | $471K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 3,008 | 2,537 | $92K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,372 | 3,842 | $81K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | <1% | 1,058 | 1,019 | $71K |
37 more codes
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 8,305 | $36K |
| 99205 | Prolong outpt/office vis | <1% | 222 | $20K |
| 87807 | <1% | 1,990 | $17K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 15,161 | $15K |
| 96127 | <1% | 3,450 | $15K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 546 | $14K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 664 | $11K |
| S9083 | Global fee urgent care centers | <1% | 568 | $11K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 632 | $8K |
| 81003 | <1% | 15,597 | $6K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 404 | $6K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,475 | $5K |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,080 | $4K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 106 | $3K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 463 | $2K |
| Q3014 | Telehealth originating site facility fee | <1% | 246 | $2K |
| 90688 | <1% | 143 | $1K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 195 | $1K |
| 99051 | <1% | 8,103 | $1K | |
| 74018 | <1% | 71 | $1K | |
| 90461 | <1% | 77 | $1K | |
| 86308 | <1% | 279 | $883.97 | |
| 99401 | <1% | 47 | $788.92 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 53 | $731.38 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 64 | $691.08 |
| 90633 | <1% | 253 | $413.67 | |
| 81025 | <1% | 88 | $377.91 | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 12 | $244.50 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 26 | $242.84 |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | <1% | 19 | $94.10 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 42 | $2.63 |
| 99499 | 0% | 1,147 | $0.00 | |
| 3725F | 0% | 959 | $0.00 | |
| 90734 | 0% | 35 | $0.00 | |
| 3008F | 0% | 8,047 | $0.00 | |
| 3351F | 0% | 794 | $0.00 | |
| 99000 | 0% | 291 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDAVIS, MATT (CHIEF FINANCIAL OFFICER)